An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions
- Acronyms PEGINVERA
- Sponsors AOP Orphan Pharmaceuticals AG
- 29 Jan 2018 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 08 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History